US 6,900,175: What Is the Claim Scope for Dalbavancin Dose-Spacing and Initial:Subsequent Dose Ratios?
US Patent 6,900,175 is directed to a dosing regimen for dalbavancin to treat a bacterial infection in a human. The core claim architecture is a method-of-treatment with three gating elements: (i) dose spacing, (ii) initial dose magnitude, and (iii) a relation between the initial dose and subsequent dose amounts. Dependent claims then narrow to skin and soft tissue infection, one subsequent dose vs multiple, and specific fixed dose embodiments.
This patent is squarely in the “regimen” space, not a compound patent. Its commercial relevance is tied to whether later competitors can design around by changing any of the regimen anchors (interval, initial dose, subsequent dose, or the initial-to-subsequent ratio constraint).
What Does Claim 1 Actually Require? (Independent Claim 1)
Claim 1 sets the broadest boundaries for infringement.
Claim 1 (method):
- Treat a bacterial infection in a human.
- Administer initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier.
- Dose spacing: each dose is separated by 5 to 10 days.
- Initial dose amount: about 500 mg to about 5000 mg.
- Dose ratio limitation: the initial dose is at least about two times the amount of dalbavancin contained in the subsequent dose.
Practical reading of Claim 1 boundaries
Claim 1 creates a three-dimensional infringement box:
1) Interval: 5-10 day separation between doses
2) Initial dose magnitude: 500-5000 mg
3) Ratio constraint: Initial ≥ 2 × Subsequent
If any one of those is not met, Claim 1 does not read on the regimen (and the dependent claims become the next check).
How Do Dependent Claims Narrow the Regimen?
Dependent claims primarily (a) lock the spacing to “about one week,” (b) change the number of subsequent doses (single vs multiple), and (c) specify particular initial/subsequent dose amounts.
Single vs Multiple Subsequent Doses
- Claim 2: single subsequent dose.
- Claim 4: multiple subsequent doses.
- Claim 3 / 5: specify the “about one week” interval and no intervening dalbavancin doses.
Spacing when narrowed to “about one week”
- Claim 3: subsequent dose administered about one week after the initial dose, without any intervening dose.
- Claim 5: multiple subsequent doses at about one week intervals, with no intervening doses.
Infection Type Limitation
- Claim 6: bacterial infection is skin and soft tissue infection.
Fixed initial dose embodiments
Claims 7-10 define initial dose “about X mg” anchors:
- Claim 7: initial dose about 1500 mg
- Claim 8: initial dose about 1000 mg
- Claim 9: initial dose about 800 mg
- Claim 10: initial dose about 500 mg
Fixed subsequent dose / subsequent dose ranges
Claims 11-15 define subsequent dose “about X mg” anchors:
- Claim 11: subsequent dose about 400 mg to 1000 mg
- Claim 12: subsequent dose about 500 mg
- Claim 13: subsequent dose about 400 mg
- Claim 14: subsequent dose about 250 mg
- Claim 15: subsequent dose about 200 mg
A specific paired embodiment (initial + subsequent)
- Claim 16: initial dose about 1000 mg and each subsequent dose about 250 mg
What Is Claim 17’s Additional Regimen Anchor?
Claim 17 introduces a more specific “about one week” embodiment with a defined initial and subsequent dose pairing.
Claim 17 requires:
- Treat a bacterial infection in a human.
- Administer initial and subsequent therapeutically effective doses of dalbavancin.
- Dose spacing: each dose separated by about one week.
- Doses:
- initial dose about 1000 mg
- each subsequent dose about 500 mg
Dependent claims 18-22 parallel the “single vs multiple” and “skin and soft tissue” limitations.
- Claim 18: single subsequent dose.
- Claim 19: single subsequent dose given about one week after initial, with no intervening dose.
- Claim 20: multiple subsequent doses.
- Claim 21: multiple subsequent doses at about one week intervals with no intervening doses.
- Claim 22: infection is skin and soft tissue infection.
Key relationship to Claim 1:
Claim 17 is a particular point inside Claim 1’s space:
- Interval is “about one week” (falls within 5-10 days).
- Initial is 1000 mg and subsequent is 500 mg.
- Ratio condition: initial (1000) is exactly 2 × subsequent (500), satisfying “at least about two times.”
This means Claim 17 is a narrower “specific regimen” claim that is strongly aligned to Claim 1’s general constraint set.
Scope Map: Claim Elements by Number
| Claim |
Interval requirement |
Initial dose requirement |
Subsequent dose requirement |
Number of subsequent doses |
Infection limitation |
| 1 |
5 to 10 days between doses |
~500 to ~5000 mg |
“subsequent” plus ratio: initial ≥ 2× subsequent |
initial + one or more subsequent doses |
none |
| 2 |
(from claim 1) |
(from claim 1) |
(from claim 1) |
single subsequent dose |
none |
| 3 |
~one week; no intervening doses |
(from claim 1) |
(from claim 1) |
single subsequent dose |
none |
| 4 |
(from claim 1) |
(from claim 1) |
(from claim 1) |
multiple subsequent doses |
none |
| 5 |
~one week intervals; no intervening doses |
(from claim 1) |
(from claim 1) |
multiple subsequent doses |
none |
| 6 |
(from claim 1) |
(from claim 1) |
(from claim 1) |
(not specified beyond claim 1) |
skin and soft tissue infection |
| 7 |
(from claim 1) |
~1500 mg |
(from claim 1) |
(not specified beyond claim 1) |
none |
| 8 |
(from claim 1) |
~1000 mg |
(from claim 1) |
(not specified beyond claim 1) |
none |
| 9 |
(from claim 1) |
~800 mg |
(from claim 1) |
(not specified beyond claim 1) |
none |
| 10 |
(from claim 1) |
~500 mg |
(from claim 1) |
(not specified beyond claim 1) |
none |
| 11 |
(from claim 1) |
(from claim 1) |
~400-1000 mg |
(not specified beyond claim 1) |
none |
| 12 |
(from claim 1) |
(from claim 1) |
~500 mg |
(not specified beyond claim 1) |
none |
| 13 |
(from claim 1) |
(from claim 1) |
~400 mg |
(not specified beyond claim 1) |
none |
| 14 |
(from claim 1) |
(from claim 1) |
~250 mg |
(not specified beyond claim 1) |
none |
| 15 |
(from claim 1) |
(from claim 1) |
~200 mg |
(not specified beyond claim 1) |
none |
| 16 |
(from claim 1) |
~1000 mg |
~250 mg |
multiple subsequent doses implied by claim 4 context only if dependent chain is correct; as written it depends on claim 1 |
none |
| 17 |
about one week |
~1000 mg |
~500 mg |
initial + subsequent(s) |
none |
| 18 |
(from claim 17) |
~1000 mg |
~500 mg |
single subsequent dose |
none |
| 19 |
~one week; no intervening doses |
~1000 mg |
~500 mg |
single subsequent dose |
none |
| 20 |
(from claim 17) |
~1000 mg |
~500 mg |
multiple subsequent doses |
none |
| 21 |
~one week intervals; no intervening doses |
~1000 mg |
~500 mg |
multiple subsequent doses |
none |
| 22 |
(from claim 17) |
~1000 mg |
~500 mg |
(not specified beyond claim 17) |
skin and soft tissue infection |
What Are the Likely Design-Around Levers?
Because Claim 1 is anchored on interval and a ratio relationship, the most direct ways to avoid infringement are to break at least one of those anchors.
1) Break the interval window (5-10 days)
- Move spacing outside 5-10 days.
- Or introduce an intervening dose (where dependent claims 3/5/19/21 require “without any intervening dose of dalbavancin”).
Claims 3/5 and 19/21 explicitly require no intervening doses in the one-week embodiments.
2) Break the initial-to-subsequent ratio
Claim 1 requires: initial ≥ about two times subsequent.
So infringement risk drops if a regimen uses:
- initial dose less than ~2× subsequent, or
- subsequent dose increased so initial is no longer “at least about two times” under the “about” standard.
3) Break the initial dose band (500-5000 mg)
Claim 1 limits initial dose to ~500-~5000 mg. If an approach uses an initial outside that range, Claim 1 does not apply.
4) Use non-overlapping subsequent dose magnitudes (relevant to dependent claims)
Dependent claims specify ranges/values for subsequent dosing (e.g., ~400-1000 mg, or ~200 mg, ~250 mg, ~400 mg, ~500 mg). A competitor may still fall under Claim 1 but could avoid dependent-claim coverage if they deviate from those specific subsequent anchors.
5) Avoid infection-type limitation in the “skin and soft tissue” sub-claims
Independent Claim 1 and Claim 17 do not restrict to skin/soft tissue. Dependent claims 6 and 22 do. Use of dalbavancin for other infection categories could narrow exposure under those dependent provisions while still leaving Claim 1 exposure.
How Broad Is This Across Dalbavancin Regimens?
Within the claim language provided, the broadest coverage is:
- Any bacterial infection in a human (no infection-type limitation in Claim 1).
- Any regimen with:
- 5-10 day spacing between doses,
- initial dose 500-5000 mg,
- subsequent dose amounts that satisfy the ratio (initial at least 2× subsequent),
- initial plus one or more subsequent doses (depending on whether Claim 2/4 is asserted).
The narrowest coverage is:
- The “about one week” regimen at:
- 1000 mg initial and 500 mg subsequent, plus
- single vs multiple subsequent doses, and
- optionally “no intervening doses,” and
- optionally “skin and soft tissue infection” (Claims 22, and others in chain depending on dependency).
Patent Landscape: How US 6,900,175 Fits in a Regimen-Claim Portfolio
This patent is a dose-and-interval claims set. In a typical dalbavancin landscape, such claims sit alongside:
- compound claims (if any existed in earlier filings),
- formulation claims (e.g., lyophilized vs solution, carrier, concentration, injection presentation),
- and other dosing/regimen patents.
Given only the claim text provided here, the landscape analysis that can be made precisely is limited to:
- what this patent covers (dose spacing, dose magnitudes, ratio constraint),
- and how it interacts with future regimen patents (potential overlap when they use the same interval/range/ratio logic).
Infringement-risk touchpoints by exact numeric embodiments
For diligence and freedom-to-operate work, the most operationally relevant embodiments in the claims are:
- ~1000 mg initial + ~500 mg subsequent at ~one week (Claim 17 and its dependents).
- ~1000 mg initial + ~250 mg subsequent (Claim 16).
- ~1500 mg initial (Claim 7) and subsequent governed by the ratio and 5-10 day spacing.
- Subsequent dose values anchored at ~200, ~250, ~400, ~500 mg and range ~400-1000 mg.
These are the numeric anchors most likely to coincide with clinical protocols and competitor label-driven regimens.
Commercial and R&D Implications (Scope to Product Strategy)
If you are developing an alternative dosing protocol
Map your regimen against these gates:
- Does it use 5-10 day separation between dalbavancin doses?
- Is your initial dose in ~500-~5000 mg?
- Does your initial:subsequent ratio keep “initial at least about two times subsequent”?
- For “about one week” versions, do you comply with “no intervening dose” constraints where those dependent claims apply?
- If targeting skin/soft tissue, be aware of the dependent infection limitation.
A small adjustment in interval or ratio can change the claim-read outcome.
If you are evaluating product launches during the patent term
The highest-exposure regimen in this claim set is:
- 1000 mg then 500 mg about one week later, with or without multiple subsequent doses, because it is explicitly claimed in Claim 17 and further constrained by dependents.
Key Takeaways
- US 6,900,175 claims a dalbavancin dosing regimen defined by interval (5-10 days) and a dose relationship: initial dose is at least about 2× the subsequent dose.
- The most explicit “center” of the patent is ~1000 mg initial and ~500 mg subsequent at about one week (Claim 17), plus variants for single or multiple subsequent doses and optional “no intervening dose.”
- Dependent claims add coverage for skin and soft tissue infections (Claims 6 and 22) and lock in specific initial and subsequent dose embodiments (Claims 7-16).
- The practical design-around levers are interval, the initial:subsequent ratio, initial dose band, and (for certain dependent claims) the presence or absence of intervening dalbavancin doses.
FAQs
1) What is the single biggest infringement gate in US 6,900,175?
The combination of 5-10 day dose spacing with the requirement that the initial dose is at least about two times the subsequent dose.
2) Does Claim 1 restrict the infection type?
No. Claim 1 covers treatment of a bacterial infection in a human; skin and soft tissue appears only in dependent claim 6 (and in the Claim 17 family via claim 22).
3) Which regimen is most explicitly claimed?
Claim 17: about 1000 mg initial dose and about 500 mg subsequent dose, with doses separated by about one week.
4) Can multiple subsequent doses fall under this patent?
Yes. Claim 4 covers multiple subsequent doses and Claim 20 is the multiple-subsequent version tied to the Claim 17 dosing pair.
5) What numeric subsequent doses are called out by dependent claims?
The dependent claim set includes subsequent dose anchors at ~400-1000 mg (range) and specific amounts of ~500 mg, ~400 mg, ~250 mg, and ~200 mg.
References
- United States Patent US 6,900,175. Claims provided in the user prompt (claims 1-22).
